Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review
Conclusion: miRNAs can be used as an indicator for the early detection and treatment of CML phase.PMID:38230979 | DOI:10.2217/bmm-2023-0575 (Source: Future Medicine: Biomarkers in Medicine)
Source: Future Medicine: Biomarkers in Medicine - January 17, 2024 Category: Internal Medicine Authors: Mohammad Parsa-Kondelaji Maryam Musavi Faezeh Barzegar Neda Abbasian Mehrdad Rostami Mohammad R Seyedtaghia Seyyed S Hashemi Mahdiyeh Modi Banafsheh Nikfar Amir A Momtazi-Borojeni Source Type: research
GSE236233 Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response
Contributors : Rebecca Warfvinge ; Shamit Soneji ; G öran KarlssonSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe advent of tyrosine kinase inhibitors (TKIs) as treatment of Chronic Myeloid Leukemia (CML) is a paradigm in molecularly targeted cancer therapy. Nonetheless, TKI insensitive leukemia stem cells (LSCs) persist in most patients, even after years of treatment. Here, we used cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) to generate high-resolution single cell multiomics maps from CML patients stratified according to molecular response (BCR-A...
Source: GEO: Gene Expression Omnibus - January 17, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Challenges in Management of Pediatric Chronic Myeloid Leukemia (pCML) in the Low-Middle Income Countries (LMICs): Insights from an International CML Foundation (iCMLf) Multi-National Survey
. (Source: Pediatric Hematology and Oncology)
Source: Pediatric Hematology and Oncology - January 17, 2024 Category: Pediatrics Authors: Nirmalya Roy MoulikArlene Harriss-BuchanGiuseppe SaglioMeinolf Suttorpa Pediatric Oncology, Tata Memorial Hospital, Mumbai, Indiab International CML foundation, UKc Clinical and Biological Sciences, University of Turin, Turin, Italyd Pediatric Hemato-Onco Source Type: research
Prognostic Impact of Bone Marrow Fibrosis And Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia
Myelofibrosis is reported in around 40% of newly diagnosed chronic myeloid leukemia (CML) patients and have an important role in the pathobiology and prognosis of CML. This retrospective study aimed to evaluate the effects of bone marrow (BM) fibrosis on disease prognosis and the effects of specific tyrosine-kinase inhibitors (TKIs) on BM fibrosis in CML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 16, 2024 Category: Hematology Authors: Mehmet Sezgin Pepeler, Mesut T ıglıoglu, Simten Dagdas, Esra Ozhamacıoglu, Unsal Han, Aynur Albayrak, Mürüvvet Seda Aydın, Gülten Korkmaz, Merve Pamukcuoğlu, Funda Ceran, Murat Albayrak, Gülsüm Ozet Tags: Original Study Source Type: research
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies
Leukemia, Published online: 13 January 2024; doi:10.1038/s41375-024-02139-4How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies (Source: Leukemia)
Source: Leukemia - January 13, 2024 Category: Hematology Authors: R üdiger Hehlmann Michael Lauseker Source Type: research
Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro
Biochimie. 2024 Jan 10;221:1-12. doi: 10.1016/j.biochi.2024.01.006. Online ahead of print.ABSTRACTGene silencing through RNA interference (RNAi) is a promising therapeutic approach for a wide range of disorders, including cancer. Non-viral gene therapy, using specific siRNAs against BCR-ABL1, can be a supportive or alternative measure to traditional chronic myeloid leukemia (CML) tyrosine kinase inhibitor (TKIs) therapies, given the prevalence of clinical TKI resistance. The main challenge for such approaches remains the development of the effective delivery system for siRNA tailored to the specific disease model. The purp...
Source: Biochimie - January 12, 2024 Category: Biochemistry Authors: Vera Vysochinskaya Yana Zabrodskaya Olesya Dovbysh Anton Emelyanov Vladimir Klimenko Nikolay Knyazev Ivan Terterov Marya Egorova Alexey Bogdanov Michael Maslov Andrey Vasin Michael Dubina Source Type: research
Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination
Myeloproliferative neoplasms (MPNs) are classified into Philadelphia (Ph) chromosome–positive chronic myeloid leukemia (CML) and Ph-negative MPNs. BCR::ABL1 translocation is the key genetic event of CML, whereas JAK2/MPL/CALR mutations are molecular aberrations of Ph-negative MPNs. Despite initially considered mutually exclusive genetic aberrations, the co-occurrence of BCR::ABL1 and JAK2 has been reported in a limited number of cases. The two genetic alterations may be identified either at the same time or JAK2 aberration may be detected in patients with a previous CML treated with tyrosine kinase inhibitors or, finally...
Source: Frontiers in Oncology - January 12, 2024 Category: Cancer & Oncology Source Type: research
Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels
AbstractChronic Myeloid Leukemia (CML) is a myeloproliferative disorder distinguished by a specific genetic anomaly known as a reciprocal translocation between chromosomes 9 and 22. This translocation causes fusion between the BCR and ABL regions. Consequently, BCR::ABL oncoprotein is formed, which plays a significant role in driving CML progression. Imatinib, a tyrosine kinase inhibitor (TKI), became the first line of drugs against CML. However, with continuous treatment, patients developed resistance against it. Indeed, to address this challenge, microRNA-based therapy emerges as a promising approach. miRNAs are 20 –25...
Source: Medical Oncology - January 12, 2024 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 313: Myeloproliferative Neoplasms: Diseases Mediated by Chronic Activation of Signal Transducer and Activator of Transcription (STAT) Proteins
ard
Myeloproliferative neoplasms (MPNs) are hematopoietic diseases characterized by the clonal expansion of single or multiple lineages of differentiated myeloid cells that accumulate in the blood and bone marrow. MPNs are grouped into distinct categories based on key clinical presentations and distinctive mutational hallmarks. These include chronic myeloid leukemia (CML), which is strongly associated with the signature BCR::ABL1 gene translocation, polycythemia vera (PV), essential thrombocythemia (ET), and primary (idiopathic) myelofibrosis (PMF), typically accompanied by molecular alterations in the JAK2, MPL, or CA...
Source: Cancers - January 11, 2024 Category: Cancer & Oncology Authors: Clifford Liongue Alister C. Ward Tags: Review Source Type: research
A review of the therapeutic role of bosutinib in chronic myeloid leukemia
The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph) –positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic phase, accelerat ed phase, or blast phase that is resistant or intolerant to prior therapy, and for newly diagnosed Ph-positive chronic phase CML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 11, 2024 Category: Hematology Authors: H.M. Kantarjian, E.J. Jabbour, J.H. Lipton, F. Castagnetti, T.H. Br ümmendorf Tags: Review Article Source Type: research
Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Dec 29:S2152-2650(23)02200-0. doi: 10.1016/j.clml.2023.12.011. Online ahead of print.ABSTRACTLong-term survival outcomes of patients with chronic myeloid leukemia in the chronic phase are now similar to those of the general population, following the introduction of ABL1 tyrosine kinase inhibitors (TKIs). Approximately 40% to 80% of patients with chronic myeloid leukemia successfully achieved treatment-free remission after the first attempt of TKI discontinuation (TFR1), after achieving a durable deep molecular response. However, the possibility of achieving treatment-free remission after a ...
Source: Clinical Lymphoma and Myeloma - January 9, 2024 Category: Cancer & Oncology Authors: Hiroshi Ureshino Kazuharu Kamachi Shinya Kimura Source Type: research
Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript
(Source: Annals of Hematology)
Source: Annals of Hematology - January 9, 2024 Category: Hematology Source Type: research
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
Conclusion: T315I was the most commonly identified BCR-ABL1 mutation in TKI-resistant CML patients of Azerbaijani origin, being associated with disease progression and poor OS.PMID:38188610 | PMC:PMC10766836 | DOI:10.3389/pore.2023.1611518 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - January 8, 2024 Category: Pathology Authors: Aypara Hasanova Chingiz Asadov Nigar Karimova Aytan Shirinova Gunay Aliyeva Zohra Alimirzoyeva Source Type: research
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
Conclusion: T315I was the most commonly identified BCR-ABL1 mutation in TKI-resistant CML patients of Azerbaijani origin, being associated with disease progression and poor OS.PMID:38188610 | PMC:PMC10766836 | DOI:10.3389/pore.2023.1611518 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - January 8, 2024 Category: Pathology Authors: Aypara Hasanova Chingiz Asadov Nigar Karimova Aytan Shirinova Gunay Aliyeva Zohra Alimirzoyeva Source Type: research
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
Conclusion: T315I was the most commonly identified BCR-ABL1 mutation in TKI-resistant CML patients of Azerbaijani origin, being associated with disease progression and poor OS.PMID:38188610 | PMC:PMC10766836 | DOI:10.3389/pore.2023.1611518 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - January 8, 2024 Category: Pathology Authors: Aypara Hasanova Chingiz Asadov Nigar Karimova Aytan Shirinova Gunay Aliyeva Zohra Alimirzoyeva Source Type: research
